BiotechTube

BBI608 + Temozolomide

Phase 1/2Completed
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glioblastoma

Conditions

Glioblastoma

Trial Timeline

Mar 1, 2015 → Jun 24, 2019

NCT ID
NCT02315534

About BBI608 + Temozolomide

BBI608 + Temozolomide is a phase 1/2 stage product being developed by Sumitomo Pharma for Glioblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02315534. Target conditions include Glioblastoma.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT02315534Phase 1/2Completed

Competing Products

20 competing products in Glioblastoma

See all competitors
ProductCompanyStageHype Score
TemferonGenenta SciencePhase 1/2
33
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
41
PLX3397Daiichi SankyoPhase 2
52
ASP8374 + cemiplimabAstellas PharmaPhase 1
33
Nimotuzumab + TemozolomideSun PharmaceuticalPhase 2
52
Gliadel + Avastin + TemodarEisaiPhase 2
52
BCNU Wafer + Irinotecan + BevacizumabEisaiPhase 1/2
41
KHK2455Kyowa KirinPre-clinical
23
olaratumab + ramucirumabEli LillyPhase 2
52
enzastaurin + temozolomideEli LillyPhase 1/2
41
enzastaurin + bevacizumab + Enzyme-inducing antiepileptic drugs (EIAED) + Non-enzyme inducing antiepileptic drugs (NEIAED)Eli LillyPhase 2
52
Temozolomide + Neratinib + QBS10072S + Abemaciclib + CC-115Eli LillyPhase 2
52
AbemaciclibEli LillyPhase 2
52
Enzastaurin 500 milligram (mg) Once Daily (QD) + Enzastaurin 250 mg Twice Daily (BID)Eli LillyPhase 2
52
Abemaciclib + LY3214996Eli LillyPhase 1
33
enzastaurin + lomustineEli LillyPhase 3
77
Galunisertib + Lomustine + PlaceboEli LillyPhase 2
52
DSP-7888 Dosing Emulsion + BevacizumabSumitomo PharmaPhase 3
77
DSP-7888Sumitomo PharmaPhase 1/2
41
Indoximod + Temozolomide + Cyclophosphamide + Etoposide + LomustineJohnson & JohnsonPhase 2
52

Other Products from Sumitomo Pharma

BlonanserinApproved
85
Mosapride + domperidoneApproved
85
levalbuterol HCl + albuterol SulfateApproved
85
LurasidoneApproved
85
placebo, isotonic ciclesonide, hypotonic ciclesonideApproved
85